中生康元

Sino-Cell Biotech is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of personalized cancer immunotherapies. The company utilizes its proprietary Neo-P platform, which integrates high-throughput sequencing and artificial intelligence to identify patient-specific neoantigens. Its diverse pipeline includes personalized mRNA-based neoantigen vaccines, dendritic cell (DC) vaccines, and adoptive cell therapies such as TCR-T and TILs. Sino-Cell Biotech's lead candidate, SC-001, is currently being evaluated in clinical trials for the treatment of advanced solid tumors, including pancreatic and gastric cancers. By focusing on tumor-specific mutations, the company aims to overcome the limitations of traditional immunotherapies and provide more effective, targeted solutions for cancer patients. Sino-Cell Biotech has secured significant backing from prominent venture capital firms to advance its innovative precision medicine portfolio.